tiprankstipranks
Company Announcements

Bioxyne Limited Upgrades Revenue Forecast Amidst Strong Growth

Story Highlights
Bioxyne Limited Upgrades Revenue Forecast Amidst Strong Growth

Bioxyne Limited ( (AU:BXN) ) has shared an update.

Bioxyne Limited has upgraded its revenue forecast for FY 2025 to $25 million, reflecting a 267% increase in revenue for the first half of the fiscal year. This growth is attributed to major contracts, a growing customer base, and an expanding product range, alongside a focus on maintaining positive cashflow and EBITDA. The company’s Breathe Life Science division plays a pivotal role, following its GMP licence approval. Bioxyne aims to expand its market share, customer base, and scale up operations while introducing new products into its distribution channels.

More about Bioxyne Limited

Bioxyne Limited is an Australian life sciences company specializing in pharmaceutical and consumer health products. It focuses on manufacturing novel medicines, with significant efforts in medical cannabis products, and holds a Good Manufacturing Practice Licence for Psilocybin and MDMA. The company also markets the Dr Watson® brand in Australia and Europe, and distributes its Lactobacillus fermentum PCC® probiotic globally.

YTD Price Performance: -6.67%

Average Trading Volume: 1,939,284

Technical Sentiment Consensus Rating: Sell

Current Market Cap: A$57.38M

Learn more about BXN stock on TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App